Harshaminder Kaur Grewal1, Sneha Sethi2. 1. Professor and Head of Department, Department of Oral Pathology, Seema Dental College and Hospital , Rishikesh, India . 2. Post-Graduate Student, Department of Oral and Maxillofacial Pathology, Maharishi Markandeshwar College of Dental Science and Research , Mullana, Ambala, India .
Abstract
BACKGROUND: Autocrine motility factor receptor (AMFR) is a tumour motility stimulating protein secreted by tumour cells. The protein encoded by this gene is a glycosylated transmembrane protein and a receptor for autocrine motility factor. It has been known to play a role in progression of neoplastic lesions. Basement membranes are specialized extracellular matrices that serve as structural barriers as well as substrates for cellular interactions. The network of type IV collagen is thought to define the scaffold integrating other components such as laminins and perlecan into highly organized supramolecular architecture. The aim of this study was to determine and evaluate the immunohistochemical expression of Type IV Collagen and Autocrine motility factor receptor in odontogenic lesions. MATERIALS AND METHODS: Immunohistochemical expression of Type IV Collagen and Autocrine motility factor receptor was evaluated in 31 odontogenic lesions, including unicystic ameloblastoma, multicystic ameloblastoma, keratocystic odontogenic tumour and ameloblastic carcinoma. Normal follicular tissue formed the control. RESULTS: Maximum expression for Type IV Collagen was seen in multicystic ameloblastoma and minimum expression in keratocystic odontogenic tumour. The maximum expression of AMFR was seen in ameloblastic carcinoma and minimum expression in multicystic ameloblastoma. CONCLUSION: The results of this study suggested an association of loss of expression of type IV Collagen with progression of lesion. AMFR expression was found to be associated with the aggressive potential of tumours.
BACKGROUND:Autocrine motility factor receptor (AMFR) is a tumour motility stimulating protein secreted by tumour cells. The protein encoded by this gene is a glycosylated transmembrane protein and a receptor for autocrine motility factor. It has been known to play a role in progression of neoplastic lesions. Basement membranes are specialized extracellular matrices that serve as structural barriers as well as substrates for cellular interactions. The network of type IV collagen is thought to define the scaffold integrating other components such as laminins and perlecan into highly organized supramolecular architecture. The aim of this study was to determine and evaluate the immunohistochemical expression of Type IV Collagen and Autocrine motility factor receptor in odontogenic lesions. MATERIALS AND METHODS: Immunohistochemical expression of Type IV Collagen and Autocrine motility factor receptor was evaluated in 31 odontogenic lesions, including unicystic ameloblastoma, multicystic ameloblastoma, keratocystic odontogenic tumour and ameloblastic carcinoma. Normal follicular tissue formed the control. RESULTS: Maximum expression for Type IV Collagen was seen in multicystic ameloblastoma and minimum expression in keratocystic odontogenic tumour. The maximum expression of AMFR was seen in ameloblastic carcinoma and minimum expression in multicystic ameloblastoma. CONCLUSION: The results of this study suggested an association of loss of expression of type IV Collagen with progression of lesion. AMFR expression was found to be associated with the aggressive potential of tumours.
Entities:
Keywords:
AMFR; Ameloblastoma; Keratocystic odontogenic tumour; Progression of odontogenic lesions; Type IV Collagen
Authors: Y Niinaka; S Oida; A Ishisaki; K Takeda; T Iimura; Y Maruoka; F Momose; A Negishi; H Ichijo; T Amagasa; S Sasaki; H Watanabe; A Raz Journal: Int J Oncol Date: 1996-09 Impact factor: 5.650
Authors: K Maruyama; H Watanabe; H Shiozaki; T Takayama; J Gofuku; H Yano; M Inoue; S Tamura; A Raz; M Monden Journal: Int J Cancer Date: 1995-10-20 Impact factor: 7.396
Authors: Juan P Rodrigo; Dario García-Carracedo; María V González; Gonzalo Mancebo; Manuel F Fresno; Juana García-Pedrero Journal: Mol Cancer Date: 2010-03-02 Impact factor: 27.401
Authors: S Nakamori; H Watanabe; M Kameyama; S Imaoka; H Furukawa; O Ishikawa; Y Sasaki; T Kabuto; A Raz Journal: Cancer Date: 1994-10-01 Impact factor: 6.860